Search results
Results from the WOW.Com Content Network
Proprietary database identifiers include those assigned by First Databank, Micromedex, MediSpan, Gold Standard Drug Database (published by Elsevier), and Cerner Multum MediSource Lexicon; these are cross-indexed by RxNorm, which also assigns a unique identifier (RxCUI) to every combination of active ingredient and dose level.
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
If Seq1 is higher than 01 it refers to variations of that active moiety. For multi-ingredient records, Seq1=01 identifies a combination of active moieties. If Seq1 is higher than 01 it refers to variations of one or more of the active moieties in the combination. Finally, Seq2 uniquely identifies the name of the record in WHODrug.
To arrive at their findings, researchers searched a database of about 42,000 recipes for oral medications in the U.S. and found that close to 93 percent contained at least one of 38 inactive ...
The Unique Ingredient Identifier (UNII) is an alphanumeric identifier linked to a substance's molecular structure or descriptive information and is generated by the Global Substance Registration System (GSRS) of the Food and Drug Administration (FDA).
Ingredient names must comply by law with EU requirements by using INCI names. [8] The cosmetic regulation laws are enforceable for important consumer safety. For example, the ingredients are listed on the ingredient declaration for the purchaser to reduce the risk of an allergic reaction to an ingredient the user has had an allergy to before.
PVP is included in the Inactive Ingredient Database for use in oral, topical, and injectable formulations. However, there have been documented cases of allergic reactions to PVP/povidone, particularly regarding subcutaneous (applied under the skin) use and situations where the PVP has come in contact with autologous serum (internal blood fluids ...
The drug must be combined with inactive ingredients by a method that ensures that the quantity of drug present is consistent in each dosage unit e.g. each tablet. The dosage should have a uniform appearance, with an acceptable taste, tablet hardness, and capsule disintegration.